BR112016030976A2 - proteínas de ligação de cd33 e cd3 biespecíficas - Google Patents

proteínas de ligação de cd33 e cd3 biespecíficas

Info

Publication number
BR112016030976A2
BR112016030976A2 BR112016030976-6A BR112016030976A BR112016030976A2 BR 112016030976 A2 BR112016030976 A2 BR 112016030976A2 BR 112016030976 A BR112016030976 A BR 112016030976A BR 112016030976 A2 BR112016030976 A2 BR 112016030976A2
Authority
BR
Brazil
Prior art keywords
binding proteins
bispecific
human
specifically bind
aml
Prior art date
Application number
BR112016030976-6A
Other languages
English (en)
Inventor
ELLWANGER Kristina
Evnin Luke
A. Fox Judith
FUCEK Ivica
Guenot Jeanmarie
KNACKMUSS Stefan
Kunkel Lori
Little Melvyn
Molkenthin Vera
RAJKOVIC Erich
Reusch Uwe
WALL Claudia
Weichel Michael
Zhukovsky Eugene
Original Assignee
Amphivena Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amphivena Therapeutics, Inc. filed Critical Amphivena Therapeutics, Inc.
Publication of BR112016030976A2 publication Critical patent/BR112016030976A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Containers Having Bodies Formed In One Piece (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

a presente invenção se refere aqui, neste requerimento de patente, a proteínas de ligação que ligam especificamente à cd33 humana, e em particular a proteínas de ligação biespecíficas que ligam especificamente à cd33 humana e à cd3 humana. também são descritos aqui, neste requerimento de patente, diacorpos em tandem biespecíficos que ligam a cd33 e a cd33, e seus usos para imunoterapia de cânceres cd33+, doenças e condições tais como leucemia mieloide aguda (em inglês, aml).
BR112016030976-6A 2014-07-01 2015-06-30 proteínas de ligação de cd33 e cd3 biespecíficas BR112016030976A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462019795P 2014-07-01 2014-07-01
US62/019,795 2014-07-01
US201562111470P 2015-02-03 2015-02-03
US62/111,470 2015-02-03
US14/642,497 2015-03-09
US14/642,497 US9212225B1 (en) 2014-07-01 2015-03-09 Bispecific CD33 and CD3 binding proteins
PCT/US2015/038666 WO2016004108A2 (en) 2014-07-01 2015-06-30 Bispecific cd33 and cd3 binding proteins

Publications (1)

Publication Number Publication Date
BR112016030976A2 true BR112016030976A2 (pt) 2018-01-30

Family

ID=54783088

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016030976-6A BR112016030976A2 (pt) 2014-07-01 2015-06-30 proteínas de ligação de cd33 e cd3 biespecíficas

Country Status (16)

Country Link
US (4) US9212225B1 (pt)
EP (2) EP3858853A1 (pt)
JP (3) JP6760849B2 (pt)
KR (1) KR102550472B1 (pt)
CN (2) CN112851820B (pt)
AU (2) AU2015284200B2 (pt)
BR (1) BR112016030976A2 (pt)
CA (1) CA2953992C (pt)
DK (1) DK3164159T3 (pt)
EA (1) EA201790060A1 (pt)
ES (1) ES2863600T3 (pt)
IL (3) IL283115B2 (pt)
MX (2) MX2017000187A (pt)
SG (2) SG10201900015XA (pt)
TW (3) TWI774238B (pt)
WO (1) WO2016004108A2 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11753469B2 (en) 2015-05-29 2023-09-12 Anji Bruno, Llc Methods of using bispecific CD33 and CD3 binding proteins

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
JP2018521004A (ja) * 2015-05-18 2018-08-02 ユーリカ セラピューティックス， インコーポレイテッド 抗ｒｏｒ１キメラ抗原受容体
US10758886B2 (en) * 2015-09-14 2020-09-01 Arizona Board Of Regents On Behalf Of Arizona State University Conditioned surfaces for in situ molecular array synthesis
WO2017055318A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Cd33xcd3 bispecific t cell activating antigen binding molecules
TWI797073B (zh) 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
JOP20170091B1 (ar) * 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
RU2019130504A (ru) 2017-02-28 2021-03-30 Вор Байофарма, Инк. Композиции и способы ингибирования линиеспецифических белков
CN115927621A (zh) * 2017-05-23 2023-04-07 杭州赫玛生物科技有限公司 用于进行白血病诊疗的系统
WO2019075413A1 (en) * 2017-10-12 2019-04-18 Amphivena Therapeutics, Inc. DOSAGE SCHEME FOR CD3 BINDING PROTEINS
JP7438106B2 (ja) 2017-10-14 2024-02-26 シートムエックス セラピューティクス，インコーポレイテッド 抗体、活性化可能抗体、二重特異性抗体、および二重特異性活性化可能抗体ならびにその使用方法
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
JP2021532140A (ja) * 2018-07-30 2021-11-25 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３３及びｃｄ３に結合する二重特異性抗体コンストラクトの長期投与
JP2022520138A (ja) 2018-08-28 2022-03-29 ブイオーアール バイオファーマ インコーポレーテッド 遺伝子操作された造血幹細胞およびそれらの使用
EP3863644A4 (en) * 2018-10-12 2022-10-05 Jeanmarie Guenot CD33×CD3-BINDING PROTEINS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS AND DISEASES
CN113396161A (zh) * 2018-12-04 2021-09-14 诺华股份有限公司 针对cd3的结合分子及其用途
KR102239781B1 (ko) * 2019-04-08 2021-04-13 주식회사 녹십자 Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
WO2020243603A1 (en) 2019-05-29 2020-12-03 Amphivena Therapeutics, Inc. Dosing of bispecific t cell engager
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
UY39488A (es) 2020-10-28 2022-04-29 Janssen Biotech Inc Composiciones y métodos para modular la inmunidad mediada por la cadena delta gamma
EP4240406A1 (en) 2020-11-05 2023-09-13 Anji Bruno, LLC Assessment of cancers for treatment with a cd33/cd3 bispecific t cell engager
JP2024523033A (ja) 2021-06-17 2024-06-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の三重特異的結合分子
EP4370557A2 (en) * 2021-07-16 2024-05-22 Medical Guidance Systems, LLC Anti-tax interacting protein-1 (tip1) binding molecules
CN116375868A (zh) * 2021-12-31 2023-07-04 康源博创生物科技(北京)有限公司 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用
CN118221826A (zh) * 2024-04-25 2024-06-21 北京绿竹生物技术股份有限公司 一种结合人cd33和cd3的双特异性抗体

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
DK1242457T3 (da) 1999-12-28 2004-12-20 Esbatech Ag Intracellulære antistoffer [intracellulære antistoffer] med defineret struktur, der er stabil i et reducerende miljö, og anvendelse deraf
EP1272647B1 (en) 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
ATE346866T1 (de) 2001-09-14 2006-12-15 Affimed Therapeutics Ag Multimerische, einzelkettige, tandem-fv- antikörper
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
ITCB20020005A1 (it) * 2002-11-12 2004-05-13 Filomena Zeoli Siringa di sicurezza con ago retrattile irreversibile.
CA2542239C (en) 2003-10-16 2014-12-30 Micromet Ag Multispecific deimmunized cd3-binders
CA2555503C (en) 2004-02-16 2018-03-27 Micromet Ag Humanized anti-cd3 bispecific binding molecules having reduced immunogenicity, uses and compositions relating thereto
JP5014988B2 (ja) 2004-07-16 2012-08-29 マイクロメット アクツィエン ゲゼルシャフト 発現増強ポリペプチド
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP3770174A1 (en) 2005-10-11 2021-01-27 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
WO2007048186A1 (en) * 2005-10-25 2007-05-03 Baker Medical Research Institute Leukocyte-binding polypeptides and uses thereof
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2007317333A1 (en) * 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
CA2683370C (en) 2007-04-03 2022-12-13 Micromet Ag Cross-species-specific binding domain
CA2738566C (en) 2008-10-01 2024-04-30 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
SG194398A1 (en) * 2008-10-01 2013-11-29 Amgen Res Munich Gmbh Cross-species-specific psmaxcd3 bispecific single chain antibody
US8563307B2 (en) * 2009-02-24 2013-10-22 James Wang Treatment of immunosuppression-related disorders
DE102009045006A1 (de) * 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
RU2580038C2 (ru) 2009-12-04 2016-04-10 Дженентек, Инк. Мультиспецифические антитела, аналоги антител, композиции и способы
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
CA2796633C (en) 2010-04-23 2020-10-27 Genentech, Inc. Production of heteromultimeric proteins
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
AU2011286024B2 (en) 2010-08-02 2014-08-07 Macrogenics, Inc. Covalent diabodies and uses thereof
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
KR101398363B1 (ko) * 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
US20140056897A1 (en) * 2011-03-10 2014-02-27 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
EP2710042A2 (en) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
BR122016016837A2 (pt) * 2011-05-21 2019-08-27 Macrogenics Inc moléculas de ligação a cd3; anticorpos de ligação a cd3; composições farmacêuticas; e usos da molécula de ligação a cd3
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JP5938473B2 (ja) * 2011-07-22 2016-06-22 アフィメート テラポイティクス アーゲー 多価抗原結合Ｆｖ分子
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CN104379601B (zh) 2012-02-03 2021-04-09 霍夫曼-拉罗奇有限公司 双特异性抗体分子和抗原-转染的t-细胞以及它们在医药中的用途
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
IN2014KN00920A (pt) 2012-06-21 2015-10-09 Compugen Ltd
CN104640562A (zh) 2012-07-13 2015-05-20 酵活有限公司 包含抗-cd3构建体的双特异性不对称异二聚体
KR101911438B1 (ko) 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
US20140213771A1 (en) 2012-12-28 2014-07-31 Abbvie, Inc. Multi-specific binding proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
ES2775207T3 (es) 2013-02-26 2020-07-24 Roche Glycart Ag Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas específicas para CD3 y CEA
AU2014236769B2 (en) 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
SI3030581T1 (sl) * 2013-08-07 2021-07-30 Affimed Gmbh Mesta za vezavo na protitelo, ki so specifična za EGFRVIII
TWI688401B (zh) * 2013-09-13 2020-03-21 美商安進公司 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
CA2987037A1 (en) * 2015-05-29 2016-12-08 Amphivena Therapeutics, Inc. Use of cd33/cd3 bispecific tandem diabodies for the treatment of acute myeloid leukemia (aml)
WO2019075413A1 (en) * 2017-10-12 2019-04-18 Amphivena Therapeutics, Inc. DOSAGE SCHEME FOR CD3 BINDING PROTEINS
EP3863644A4 (en) * 2018-10-12 2022-10-05 Jeanmarie Guenot CD33×CD3-BINDING PROTEINS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS AND DISEASES
WO2020243603A1 (en) * 2019-05-29 2020-12-03 Amphivena Therapeutics, Inc. Dosing of bispecific t cell engager

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11753469B2 (en) 2015-05-29 2023-09-12 Anji Bruno, Llc Methods of using bispecific CD33 and CD3 binding proteins

Also Published As

Publication number Publication date
TW202146462A (zh) 2021-12-16
AU2015284200A1 (en) 2017-02-02
TWI787142B (zh) 2022-12-11
IL283115A (en) 2021-06-30
EP3164159A2 (en) 2017-05-10
ES2863600T3 (es) 2021-10-11
US20160194409A1 (en) 2016-07-07
US9803029B2 (en) 2017-10-31
EA201790060A1 (ru) 2017-08-31
CN106794266B (zh) 2021-02-23
AU2015284200B2 (en) 2020-07-02
EP3858853A1 (en) 2021-08-04
CN112851820B (zh) 2023-11-28
CA2953992A1 (en) 2016-01-07
SG11201610973YA (en) 2017-01-27
EP3164159A4 (en) 2018-01-17
US20160002333A1 (en) 2016-01-07
TWI774238B (zh) 2022-08-11
MX2021002912A (es) 2021-06-15
JP2022068346A (ja) 2022-05-09
JP2017521415A (ja) 2017-08-03
SG10201900015XA (en) 2019-02-27
IL283115B1 (en) 2023-10-01
IL274892A (en) 2020-07-30
KR20170041697A (ko) 2017-04-17
IL249802A0 (en) 2017-03-30
CN112851820A (zh) 2021-05-28
JP2020147599A (ja) 2020-09-17
KR102550472B1 (ko) 2023-06-30
TW201613973A (en) 2016-04-16
US10626190B2 (en) 2020-04-21
IL274892B (en) 2021-07-29
DK3164159T3 (da) 2021-03-29
MX2017000187A (es) 2017-06-30
WO2016004108A2 (en) 2016-01-07
IL283115B2 (en) 2024-02-01
US9212225B1 (en) 2015-12-15
US20180291113A1 (en) 2018-10-11
EP3164159B1 (en) 2020-12-30
JP6760849B2 (ja) 2020-09-23
AU2020244593A1 (en) 2020-11-05
TWI721950B (zh) 2021-03-21
WO2016004108A3 (en) 2016-04-07
TW202241969A (zh) 2022-11-01
CN106794266A (zh) 2017-05-31
CA2953992C (en) 2023-10-03
JP7065149B2 (ja) 2022-05-11
US20210024654A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
BR112016030976A2 (pt) proteínas de ligação de cd33 e cd3 biespecíficas
BR112017025479A2 (pt) métodos para utilizar proteínas de ligação cd33 e cd3 biespecíficas
CO2018001485A2 (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7 - h3 y cd3
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
ECSP17042921A (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda
BR112017020054A2 (pt) anticorpos para icos
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
PH12016501763A1 (en) Multispecific antibodies
IL255076A0 (en) Bispecific antibody constructs for cdh3 and cd3
BR112017007170A2 (pt) anticorpos anti-ox40 humanizados e suas utilizações
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2016016883A (es) Anticuerpo anti-axl.
BR112018075858A2 (pt) anticorpos anti-fator xi de coagulação
BR112018067897A2 (pt) imunoglobulinas modificadas com ligação de fcrn alterada
BR112016021066A2 (pt) anticorpos humanizados com estabilidade aumentada
BR112019010139A2 (pt) polipeptídeos biespecíficos para gitr e ctla-4
AR121863A2 (es) Proteínas biespecíficas de unión a cd33 y cd3
NZ733664A (en) Antibodies that bind human c6 and uses thereof
AR105714A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
TWI858372B (zh) Ｃｄｈ３與ｃｄ３之雙特異性抗體構築體
CR20170233A (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.